Sabril 500mg Tablets

Sabril 500 mg Tablets contain vigabatrin, an antiepileptic medicine that increases the availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain. It is prescribed for specific seizure disorders when other treatments have not provided adequate control or when it is appropriate under the relevant product authorization.

Depending on the country-specific product labeling, Sabril may be used alongside other antiepileptic medicines for treatment-resistant partial seizures and as monotherapy for infantile spasms (West syndrome).

Vigabatrin requires specialist supervision because it can cause serious and potentially permanent damage to vision.

Product Information

Product Name

Sabril 500 mg Tablets

Active Ingredient

Vigabatrin

Strength

500 mg per tablet

Dosage Form

Film-coated tablet

Drug Class

Antiepileptic medicine

Route of Administration

Oral

Manufacturer/Brand Holder

Verify current product packaging

Pack Size

Confirm available packaging

Prescription Requirement

Prescription-only, subject to local regulations

Ordering and Availability

For Sabril 500 mg tablet pricing, pack sizes and availability, contact the supplier to verify the exact product, manufacturer, current stock and supporting documentation.

Product authorization, dispensing requirements and import eligibility differ by country. Confirm local regulations and obtain the medicine through an authorized pharmacy or eligible supplier.

Sabril 500 mg Tablets may be prescribed for:

• Treatment-Resistant Partial Seizures: Used with other antiepileptic medicines when appropriate alternative treatments have been inadequate or not tolerated.
• Infantile Spasms: Vigabatrin may be used as monotherapy for infantile spasms under specialist supervision, according to the applicable product labeling.

The exact approved indications and eligible patient groups vary by country. Treatment suitability must be determined by a specialist.

Take Sabril 500 mg Tablets exactly as prescribed by a specialist. The dose and treatment schedule depend on the patient's age, diagnosis, response to treatment, kidney function and other clinical factors.

Swallow or administer the medicine according to the official product instructions. Do not change the dose, stop treatment suddenly or use it for another condition without medical guidance.

Regular specialist reviews are required to evaluate treatment effectiveness, ongoing need and adverse effects.

Storage Instructions

Store Sabril according to the product packaging and official patient information leaflet. Keep tablets in their original packaging where appropriate, away from children, and do not use them after the expiry date.

Possible adverse effects include:

• Drowsiness or fatigue
• Dizziness
• Blurred vision or other visual changes
• Weight gain
• Headache
• Reduced coordination or tremor
• Confusion or mood changes

Vision loss is a major safety concern. Vigabatrin can cause progressive, potentially permanent visual-field loss. Vision damage may occur even when the patient does not notice symptoms. Baseline and regular vision assessments are essential during treatment and as advised after treatment ends.

Seek medical advice promptly for new visual symptoms, unusual behaviour, significant mood changes or worsening seizures. Severe or sudden symptoms require urgent assessment.

Sabril should be initiated and monitored by an appropriate specialist. Before treatment, inform the healthcare professional about existing visual problems, kidney disease, mental health history and all current medicines.

Important precautions include:

• Vision monitoring: Regular assessments are necessary because visual-field damage may be irreversible.
• Kidney function: Vigabatrin is eliminated through the kidneys, so dose adjustment may be necessary in renal impairment.
• Seizure control: The medicine should not be withdrawn abruptly; discontinuation generally requires gradual reduction under medical supervision.
• Other medicines: Tell the prescriber about all antiepileptic medicines and other treatments to assess interactions and combined adverse effects.
• Pregnancy and breastfeeding: Discuss potential risks and benefits with the treating specialist before use.

Treatment should be continued only when its expected benefits justify the risks and when ongoing monitoring can be maintained.